Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 26 | 1 | 25 | 0 |
| Shares | 4.45M | 10 | 4.37M | −80.8K (−1.8%) |
| Value | $11.1M | $25 | $12.8M | +$1.69M (+15.3%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| NBC Securities, Inc. | 150 | $1.00K | 0.00% |
| FMR LLC | 13 | $38 | 0.00% |
Sold out (2)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Rhumbline Advisers | 66 | $164 |
| Lindbrook Capital, LLC | 4 | $10 |
Not filed for Q1 2024 yet (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Coppell Advisory Solutions LLC | 10 | $25 |